Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Brienza

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Immunomodulating properties of bestatin in cancer patients. A phase II trialG Mathé, H Umezawa, J L Misset, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancerP Chollet, M A Bensmaïne, S Brienza, et al.
American Journal of Clinical Oncology|June 17, 1998
Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracilF deBraud, E Munzone, F Nolè, et al.
Revue Medicale De Bruxelles|November 24, 2015
[Rehabilitation after total knee arthroplasty of hip and knee]E Jansen, S Brienza, A Gierasimowicz-Fontana, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2002
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequencesM Boisdron-Celle, C Craipeau, S Brienza, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|June 30, 2016
Modifying the Primary Care Exception Rule to Require Competency-Based AssessmentDaniel G Tobin, Benjamin R Doolittle, Matthew S Ellman, et al.
The Journal of Infusional Chemotherapy|January 1, 1995
Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trialP Deprés-Brummer, F Berthault-Cvitkovic, F Lĕvi, et al.
Anti-Cancer Drugs|June 23, 1998
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancerB Gerard, H Bleiberg, D Van Daele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II studyC Garufi, C Nisticò, S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinomaF Bertheault-Cvitkovic, F Lévi, S Soussan, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Immunomodulating properties of bestatin in cancer patients. A phase II trialG Mathé, H Umezawa, J L Misset, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancerP Chollet, M A Bensmaïne, S Brienza, et al.
American Journal of Clinical Oncology|June 17, 1998
Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracilF deBraud, E Munzone, F Nolè, et al.
Revue Medicale De Bruxelles|November 24, 2015
[Rehabilitation after total knee arthroplasty of hip and knee]E Jansen, S Brienza, A Gierasimowicz-Fontana, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2002
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequencesM Boisdron-Celle, C Craipeau, S Brienza, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|June 30, 2016
Modifying the Primary Care Exception Rule to Require Competency-Based AssessmentDaniel G Tobin, Benjamin R Doolittle, Matthew S Ellman, et al.
The Journal of Infusional Chemotherapy|January 1, 1995
Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trialP Deprés-Brummer, F Berthault-Cvitkovic, F Lĕvi, et al.
Anti-Cancer Drugs|June 23, 1998
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancerB Gerard, H Bleiberg, D Van Daele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II studyC Garufi, C Nisticò, S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinomaF Bertheault-Cvitkovic, F Lévi, S Soussan, et al.
Pageof 6